ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium
Affiliations: Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany, Department of Digestive Diseases and Internal Medicine Sant'Orsola-Malpighi Hospital, Bologna, Italy, Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic, Pancreas Biomedical Research Unit and the Liverpool Experimental Cancer Medicine Centre, National Institute for Health Research, Liverpool, UK, Digestive and Liver Disease Unit, ‘Sapienza' University of Rome, Rome, Italy, Department of Digestive Tract Diseases, Medical University, Lodz, Poland, Clinic for General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany, Department of Hematology, Medical University, Lodz, Poland, University of Cambridge School of Clinical Medicine, Cambridge, UK, Cancer Epidemiology Unit, University of Oxford, Oxford, UK, Blood Transfusion Service, Azienda Ospedaliero Universitaria Meyer, Florence, Italy, Department of Biology, University of Pisa, Pisa, Italy, Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Science of the Czech Republic and First Faculty of Medicine, Charles University in Prague, Czech Republic, Medical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, Heidelberg University, German Red Cross Blood Service of Baden-Württemberg-Hessen, Mannheim, Germany
- Published online on: February 12, 2013 https://doi.org/10.3892/or.2013.2285
- Pages: 1637-1644
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...
This article is mentioned in:
There is strong epidemiologic evidence indicating that common genetic variability could be implicated in pancreatic cancer risk and, to date, various loci have been proposed. In particular, there is increasing evidence of the involvement of ABO gene variability and pancreatic cancer risk. In a large multicentric study of 1,028 pancreatic ductal adenocarcinoma cases and 2,257 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium, we investigated the suggested association with increased risk for carriers of single nucleotide polymorphisms (SNPs) determining the A or B allele in comparison with the O allele, which encodes for a non-functional enzyme. Since glycosyltransferase activity, encoded by ABO, is higher for the A1 variant compared with the A2 variant, we investigated the hypothesis that A1 carriers were at an increased risk of pancreatic cancer. In our analysis, carriers of the A1 were indeed at greater risk of developing the disease. In addition, we investigated the possible influence that genetic variability at the ABO locus may have in pancreatic cancer survival, but we observed no effect in our population.